ストックスクリーナーアプリを入手
19.04
18.35%
-3.985
前日終値:
$23.02
開ける：
$17.83
24時間の取引高:
121.48M
Relative Volume:
5.79
時価総額：
$4.30B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
27.59
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
-28.91%
1か月 パフォーマンス:
-40.69%
6か月 パフォーマンス:
-63.81%
1年 パフォーマンス:
-55.83%
1日の値動き範囲:
$16.35
$19.17
1週間の範囲:
$16.35
$27.77
52週間の値動き範囲:
$16.35
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
18.88 | 5.24B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.75 | 56.52B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.97 | 56.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.86 | 48.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.49 | 39.90B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
471.01 | 20.90B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Novo Nordisk Escalates Fight Against Hims & Hers - The Wall Street Journal
Hims & Hers Health: The Company Will Survive, But Investors Should Expect A 'Washout' - Seeking Alpha
FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast - Benzinga
Novo Nordisk says it’s suing Hims to halt obesity drug copycats - Ad Age
BofA Securities lowers Hims and Hers stock price target on Novo Nordisk lawsuit - Investing.com
Hims & Hers Shares Plunge as Novo Files Lawsuit Amid Telehealth Firm's Regulatory Scrutiny - marketscreener.com
Hims & Hers Under Fire, Stock Tanks on Federal Crackdown, Patent War - Benzinga
Why Hims & Hers stock just got destroyed - MSN
Hims offered a $49 weight loss pill, then yanked it. Now Novo Nordisk is suing.Straight Arrow News - Straight Arrow News - SAN
HIMS Stock Plummets Over 23% to $17.68 - GuruFocus
These Stocks Are Today’s Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More - Barron's
Hims & Hers Health Faces Legal and Regulatory Challenges, Stock Plummets - GuruFocus
HIMS: Analyst TD Cowen Lowers Price Target, Maintains Hold Ratin - GuruFocus
Novo Says It’s Suing Hims to Halt Obesity Drug Copycats - bloomberg.com
HIMS’ 34% Pullback Reflects Rising Regulatory Risk - Trefis
Why Hims & Hers Health (HIMS) Stock Is Nosediving - Finviz
Why Hims & Hers Stock Just Got Destroyed - Nasdaq
HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment - Yahoo Finance
HIMS Stock Rating Updated: Citigroup Lowers Price Target to $16. - GuruFocus
Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
Stocks making the biggest moves midday: Oracle, Cleveland-Cliffs, Kyndryl, Nexstar, Workday, Hims & Hers - CNBC
Hims & Hers Faces New Risk as All GLP-1 Compounding Could be Restricted, BofA Says - marketscreener.com
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash - FinancialContent
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn - Investopedia
Novo Nordisk sues Hims & Hers over alleged copycat drugs - Modern Healthcare News
HIMS Stock Experiences Significant Drop of 25.8% - GuruFocus
Novo sues Hims & Hers despite Wegovy pill offering U-turn - Yahoo Finance
Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron's
Hims & Hers (HIMS) Faces Regulatory Scrutiny Over Unapproved Dru - GuruFocus
FDA announces actions against telehealth compounding company Hims and Hers on the same day Novo Nordisk sues over Wegovy - Tri-State Alert
Hims & Hers stock crashes after FDA announces plans to take 'decisive steps' against GLP-1 compounds - Yahoo Finance
Novo Nordisk has lost most of its post-Wegovy market cap gains - Sherwood News
Stock Movers: Alphabet, Hims & Hers Health, Tegna - bloomberg.com
Kyndryl, Hims & Hers, Novo Nordisk, Valaris, Monday.com, Cleveland-Cliffs, and More Movers - Barron's
Biggest stock movers Monday: VAL, KD, HIMS, and more - Seeking Alpha
Hims & Hers Halts Semaglutide Pills Amid Regulatory Scrutiny - StocksToTrade
Gottlieb says Hims & Hers risks DOJ action over unapproved GLP-1 rival to Novo Nordisk- CNBC interview - Seeking Alpha
Hims & Hers Stock Plunges 25%. Its Weight Loss Drug Strategy Backfired. - Barron's
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs - Benzinga
Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs - Benzinga
Novo-Nordisk A/S rose more than 5% at the market opening as its competitor HIMS withdrew plans for a low-cost generic weight-loss drug. - 富途牛牛
Eli Lilly buys Orna, Novo Nordisk sues Hims & Hers, Kyndryl plunges - Yahoo Finance
Novo says it’s suing Hims to halt obesity drug copycats - The Detroit News
Novo Nordisk Sues Hims & Hers, Seeking Ban on Copycat Drugs and Damages - The Wall Street Journal
Novo files patent suit against Hims (update) (HIMS:NYSE) - Seeking Alpha
Shake-up in HIMS and Novo Nordisk shares⚡A lawsuit in the background... 🏛️ - XTB.com
Stock Movers: Hims & Hers, Eli Lilly, Alphabet - bloomberg.com
Hims & Hers retreats from compounded GLP-1 pill - Axios
Hims & Hers scraps low-cost weight-loss pill following backlash - Proactive financial news
'Health Risk': Novo Nordisk Sues Hims & Hers Over Cheaper Version Of Ozempic, Wegovy Fat Loss Pills - NDTV Profit
AI for investors - MLQ.ai
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
0.89%
2.24%
大文字化:
|
ボリューム (24 時間):